January 30, 2008Open Access

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Benchmarks are provided for 1-year OS or OS curves that make use of the distribution of prognostic factors of the patients in the phase II trial. A similar benchmark for 6-month PFS is provided, but its use is more problematic because of residual between-trial variation in this endpoint.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Korn et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8cbaa270e68ba94bed8dd https://doi.org/https://doi.org/10.1200/jco.2007.12.7837

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials2001 · 57 citations
2Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials2000 · 376 citations
3Evaluation of fludarabine phosphate in malignant melanoma1991 · 11 citations
4Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.1998 · 54 citations
5When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival2007 · 174 citations

Me gusta

Guardar

Ver artículo completo